Independent, catalyst-driven research on biopharma & medical device stocks.
Biotech Currents is a publication started by SanaCurrents ("SC"), a service established to identify which stocks, valued entirely on the promise of developing a new, novel drug, has the best chance for value appreciation. Life science investing always has been a roller coaster ride, as well as a minefield, usually with more deep dips than gradual climbs, and our reports aim to navigate the volatility with data-driven analysis.
Unlike a Merck, Medtronic or Pfizer that are partly valued on sales, small biopharma and device stocks rise and fall on how well the companies advance new therapies. To develop a new therapy for patients, companies must deliver a drug that is a step up from the current standard of care, presents a value proposition for clinicians, and then move it to the marketplace with smart design of its clinical trials.
SanaCurrents developed a set of objective data points related to clinical testing and the value proposition of drugs and devices in development.
Featured catalyst reports come with a MACE score. MACE stands for:
Market Demand
Adoption by payers and key opinion leaders (KOLs)
Clinical progress
Experience and capital.
The four components of MACE are combined to provide an overall probability score for the catalyst.
SanaCurrents typically has 12-20 pending catalysts at any time during the year. Institutional subscribers gain immediate access to all pending catalysts, creating the opportunity to build gains quickly. Institutional subscribers also gain access to four years of SanaCurrents reports.
SanaCurrents applies these data points to assess how likely a company will be able to advance a drug or device, helping us to determine our decision to potentially buy the stock.
The data points provide the foundation for SanaCurrents’ proprietary analytics-based model, which identifies the therapies and companies SanaCurrents believes most likely to increase in value prior to a pivotal announcement. Examples of pivotal announcements would be the results of a clinical study or the publication of data in an influential scientific journal.
To date, SanaCurrents has written more than 200 reports at sanacurrents.com, and has made the easy decision to spread the analysis to a wider audience here at Substack.
About Me
Before starting SanaCurrents, I spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo, Reuters Health and the investor news service MergerMarket. During that time, I wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work.
One constant truth I learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma, small companies typically fly under the radar of investors. The emergence of precision medicine, however, strengthens the value of new medicines in development and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies of benefit to patients and investors.
To further expand the reach of my current research on select catalysts in the biotech space, I started Biotech Currents here on Substack. Thanks for reading, and I hope you enjoy it!
~ Bill Langbein
Founding Partner
SanaCurrents
Disclaimer:
Biotech Currents (d/b/a SanaCurrents™) publishes Information regarding certain stocks (collectively, “Securities”) that we believe may interest our Users. The Information is provided for information purposes only, and SanaCurrents™ is not engaged in rendering investment advice or providing specific investment-related recommendations, nor does SanaCurrents™ solicit the purchase of or sale of, or offer any, Securities featured by and/or through SanaCurrents™ Offerings and nothing we do and no element of the SanaCurrents™ Offerings should be construed as such. Without limiting the foregoing, the Information is not intended to be construed as a recommendation to buy, hold or sell any specific Securities, or otherwise invest in any specific Securities. Trading in Securities involves risk and volatility. Past results are not necessarily indicative of future performance.
You acknowledge and agree that use of SanaCurrents™ Information is at your own risk. In no event will SanaCurrents™ or any affiliated party be liable for any direct or indirect trading losses caused by any Information featured by and through the SanaCurrents™ Offerings. You agree to do your own research and due diligence before making any investment decision with respect to Securities featured by and through the SanaCurrents™ Offerings. You represent to SanaCurrents™ that you have sufficient investment sophistication to critically assess the Information. If you choose to engage in trading or investing that you do not fully understand, we may not advise you regarding the applicable trade or investment. We also may not directly discuss personal trading or investing ideas with you. The Information made available by and through the SanaCurrents™ Offerings is not a substitute for professional financial advice. You should always check with your professional financial, legal and tax advisors to be sure that any Securities, investments, advice, products and/or services featured by and through the SanaCurrents™ Offerings, as well as any associated risks, are appropriate for you.
